Patent US4096252A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4096252A Expired / Lapsed US ⏱️ 0.0 years remaining

4-Trifluoromethylbenzoic acid derivatives as thromboembolic agents

Assignee: Noucor Health SA
•
Filing: 1976-06-10
•
Granted: 1978-06-20
•
Expires: 1996-06-10
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract 2-OR-4-trifluoromethylbenzoic acid wherein R is H or acyl. The compounds are useful in the treatment of pathological cardiovascular conditions, particularly in the prophylaxis of the thromboembolic diseases. The compounds are made by reacting m-trifluoromethyl phenol with potassium carbonate and carbon dioxide at an elevated temperature and pressure and, if desired, acetylating the 2-OH compound thus obtained or reacting it with a phosphonating agent. The invention also embraces pharmaceutical compositions in which the compounds constitute the effective agent and a method of treatment.

Inventors

  • 👤 Emilia Francia Barra
  • 👤 Antonio Carmelo Marin Moga

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-07 07:19
CPC Classifications
C; C07; C07F; C07F9/00; C07F9/02; C07F9/06; C07F9/08; C07F9/09; C07F9/12; A; A61; A61P; A61P7/00; A61P7/02; C07C; C07C51/00; C07C51/15

Claims Analysis

Total Claims: 3
Claim 1
Independent Claim 91 words
A method for the treatment and prophylaxis of cardiovascular conditions due to an abnormal platelet aggregation, coagulation and fibrinolysis comprising administering to a patient by oral administration a compound of the formula ##STR6## wherein R is hydrogen or lower alkanoyl as active agent, together with a carrier therefor, at a dosage of about 1 to 6 unit doses of about 200 to 300 mg each of said active agent or about 1 to 6 units at about 5 ml each of the active agent when in the form of a syrup.
Claim 2
Independent Claim 91 words
A method for the treatment and prophylaxis of cardiovascular conditions due to an abnormal platelet aggregation, coagulation and fibrinolysis comprising administering to a patient by oral administration a compound of the formula ##STR6## wherein R is hydrogen or lower alkanoyl as active agent, together with a carrier therefor, at a dosage of about 1 to 6 unit doses of about 200 to 300 mg each of said active agent or about 1 to 6 units at about 5 ml each of the active agent when in the form of a syrup.
Claim 3
Dependent Claim 13 words
The method of claim 1 wherein the said active agent is 2-acetoxy-4-trifluoromethylbenzoic acid.

References Cited (Backward Citations)

US3019253A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1981-06-19 1981-12-19 1982-06-20 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1985-06-19 1985-12-19 1986-06-20 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1989-06-19 1989-12-19 1990-06-20 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag